RESULTS
t e c h n i c a l r e p o r t s Delayed myeloid engraftment after cord blood transplantation (CBT) is thought to result from inadequate numbers of progenitor cells in the graft and is associated with increased early transplant-related morbidity and mortality. New culture strategies that increase the number of cord blood progenitors capable of rapid myeloid engraftment after CBT would allow more widespread use of this stem cell source for transplantation. Here we report the development of a clinically relevant Notch-mediated ex vivo expansion system for human CD34 + cord blood progenitors that results in a marked increase in the absolute number of stem/progenitor cells, including those capable of enhanced repopulation in the marrow of immunodeficient nonobese diabetic-severe combined immunodeficient (NOD-SCID) mice. Furthermore, when cord blood progenitors expanded ex vivo in the presence of Notch ligand were infused in a clinical setting after a myeloablative preparative regimen for stem cell transplantation, the time to neutrophil recovery was substantially shortened. To our knowledge, this is the first instance of rapid engraftment derived from ex vivo expanded stem/progenitor cells in humans.
Cord blood is an effective and widely used source of stem cells for individuals undergoing hematopoietic stem cell transplantation. Most patients now receive two units of cord blood derived from different donors to better ensure provision of adequate stem cell numbers for reliable donor engraftment. However, the time to donor engraftment remains relatively delayed, averaging more than 3 weeks to achieve adequate numbers of myeloid cells. This leaves patients susceptible to infection with increased risk of morbidity and mortality. Previous efforts to improve the rate of engraftment using ex vivo cytokinemediated expansion methodologies to generate increased numbers of cells have not shown significant clinical effects [1] [2] [3] . To address this, our laboratory has investigated the role of the Notch signaling pathway in regulating ex vivo expansion of hematopoietic stem/progenitor cells (HSPCs), with the goal of generating increased numbers of progenitor cells capable of rapid repopulation in vivo to improve the kinetics of hematopoietic recovery after CBT.
A role for Notch in hematopoiesis was initially suggested by our detection of the human Notch1 gene in CD34 + or CD34 + lin − human hematopoietic precursors 4 and by the enhanced self-renewal of repopulating cells resulting from retrovirus-mediated expression of a constitutively active form of Notch1 (ref. 5 ). Subsequently, activation of endogenous Notch receptors by immobilized Notch ligand revealed profound effects on the growth and differentiation of mouse marrow progenitor cells with a multilog increase in the number of precursor cells with short-term lymphoid and myeloid repopulating ability 6 . For human cells, incubation of cord blood progenitors in the presence of immobilized ligand generated an approximate 100-fold increase in the number of CD34 + cells with enhanced repopulating ability in an immunodeficient mouse model 7, 8 . Overall, these observations demonstrated that Notch signaling has a key regulatory role in hematopoiesis and suggest that Notch ligands will be useful reagents for improving ex vivo culture of stem/progenitor cells.
Here we report the development of an optimized, clinically feasible methodology for generating cord blood stem/progenitor cells for clinical evaluation. Ex vivo culture of CD34 + cord blood stem/progenitor cells in the presence of Notch ligand resulted in a greater than 100-fold increase in CD34 + cells that repopulate immunodeficient mice with markedly enhanced kinetics and magnitude and that provide more rapid myeloid engraftment in a clinical phase 1 myeloablative CBT trial. t e c h n i c a l r e p o r t s 100 ng ml −1 interleukin-6 (IL-6) and 10 ng ml −1 IL-3). Delta1 ext-IgG consists of the extracellular domain of Delta1 fused to the Fc domain of human IgG1. We observed no significant difference in absolute numbers of CD34 + cells generated, with a CD34 + cell fold expansion of 138 ± 64 and 163 ± 64, (mean ± s.e.m., P = 0.1612, data not shown) for the CD34 + and CD34 + CD38 − starting cell populations, respectively. Assessment of in vivo NOD-SCID repopulating ability at 3, 6 and 10 weeks after infusion revealed enhanced human engraftment in the marrow of recipient mice when we used CD34 + cells as compared to CD34 + CD38 − cells (mean percentage of CD45 + in CD34 + versus CD34 + CD38 − starting cell populations cultured in the presence of Delta1 ext-IgG for 3 weeks, 6.7% versus 1.6%, P = 0.02 and for 10 weeks, 1.0% versus 0.2%, P = 0.1). We further determined that the 5GF combination was superior to using fewer cytokines for in vitro generation of CD34 + cells, as determined by limiting-dilution analysis of SRC frequency (Supplementary Fig. 1) .
We evaluated multiple, closed-system tissue culture bags and tissue culture-treated and non-tissue culture-treated flasks for ligand binding and growth of cells (detailed in the Online Methods). We also evaluated commercially available, clinical-grade serum-free media. On the basis of in vitro generation of CD34 + cells and NOD-SCID repopulating ability, we found StemSpan serum-free expansion medium and X-fold tissue culture bags (Baxter) and Nunc flasks to be superior (data not shown). Details regarding the methods for large-scale production of cGMPengineered Delta1 ext-IgG can be found in the Supplementary Methods.
We validated the reproducibility of this optimized culture system under cGMP conditions in 19 runs of cord blood units previously cryopreserved as part of the National Heart, Lung, and Blood Institute (NHLBI) Cord Blood Transplantation Study (obtained via the NHLBI repository). We observed consistent growth, averaging a greater than 150-fold expansion of CD34 + cells regardless of the starting purity, which ranged from 19% to 95% (mean 64% ± 5.2%, s.e.m.), with the low 19% purity value being an outlier ( Table 1 ). All validation run experiments resulted in detectable engraftment of human CD45 + cells in immunodeficient mice ( Table 1) .
We further evaluated the functional properties of cells generated from CD34 + starting cell populations selected from pooled fresh cord blood and cryopreserved until use. We found a 222 ± 57 (mean ± s.e.m., n = 5) fold expansion of CD34 + cells cultured in the presence of Delta1 ext-IgG versus a 68 ± 30 fold expansion for cells cultured in the presence of control IgG (P = 0.006). The repopulating ability and SRC frequency, as determined by limiting-dilution analysis, was significantly higher in mice receiving cells cultured with Delta1 ext-IgG (P < 0.0001), and resulted in both myeloid and lymphoid human cell engraftment (Fig. 1a) . The observed increase in overall human hematopoietic reconstitution at 9 versus 3 weeks after culture with Delta1 ext-IgG resulted from an increase in engrafted lymphoid cells (Fig. 1a) . Myeloid engraftment decreased somewhat, suggesting at least a portion of the starting engrafting cells were short term in nature (Fig. 1a) . However, the continued presence of at least some longer-term repopulating cells after ex vivo culture was suggested after secondary transplantation of whole marrow from NOD-SCID IL-2 receptor γ (IL-2Rγ)-null mice 17-22 weeks previously transplanted with expanded cells, which revealed human engraftment (defined as ≥ 0.5% human CD45 + cells) in the marrow of seven out of eleven secondary recipient (NOD-SCID IL-2Rγ-null) mice (Supplementary Fig. 2) . Moreover, we found that SRC frequency was markedly enhanced, with a limitingdilution analysis showing a 15.6-fold increase in SRC frequency in mice that received Delta1 ext-IgG -cultured cells as compared to those receiving noncultured cells at 3 weeks after transplant (P = 0.0001) and a 6.2 fold increase in SRC frequency at 9 weeks after transplant (P = 0.0001) ( Table 2 ). To our knowledge, this is the highest reported increase of human SRC frequency reported to date [9] [10] [11] .
Furthermore, the fold increase in repopulating cells revealed in these limiting-dilution assays suggests that the observed increase in overall human cell engraftment in mice receiving Delta1-cultured cells resulted mainly or completely from the generation of repopulating cells as a direct result of culture with Notch ligand.
A crucial factor in the future clinical efficacy of this approach is whether more rapid engraftment could be achieved after Notch-mediated expansion. In three independent experiments, we observed t e c h n i c a l r e p o r t s measurable human cell engraftment at 10 d after transplant (defined as ≥ 0.5% human CD45 + cells in the marrow of recipient mice) in all mice receiving Delta1-cultured cells, whereas no mice receiving noncultured cord blood cells showed human engraftment (Fig. 1b) . This engraftment consisted of >95% myeloid cells, as determined by expression of the human antigens CD33 and CD45 (data not shown), indicating the ability of Notch-expanded cord blood progenitors to provide markedly accelerated hematopoietic repopulation in this mouse model system.
Preliminary results of phase 1 trial
A phase 1 trial involving transplantation of a unmanipulated unit along with cord blood progenitors from a second cord blood unit that have undergone Notch-mediated ex vivo expansion is ongoing. The primary objective is evaluation of the safety of infusing the ex vivoexpanded cord blood progenitors, whereas the secondary objectives include evaluation of the kinetics and durability of hematopoietic reconstitution and the relative contribution to engraftment provided by the expanded and unmanipulated cord blood units.
To date, we have enrolled ten subjects with high-risk acute leukemias in morphologic remission at the time of transplant (Supplementary Table 1 ) with a median age of 27.5 years (range 3 to 43 years) and median weight of 61.5 kg (range 16 to 79 kg). On the basis of previous studies demonstrating the safety of double cord blood unit infusion, we gave the patients a myeloablative preparative regimen (1,320 cGy total body radiation, 120 mg per kg body weight cytoxan and 75 mg per m −2 fludarabine) followed by infusion of one unmanipulated and one ex vivo-expanded cord blood graft. We chose cord blood donors on the basis of cell dose and human leukocyte antigen (HLA) phenotype, with all units being matched to the recipient at a minimum of four out of six loci (intermediate resolution at HLA-A and HLA-B and high resolution at HLA-DRB1) and at least three of six matched to each other (Supplementary Table 1 ). Additional criteria for donor cord blood selection included a minimum requirement of a total nucleated cell (TNC) dose in the unmanipulated graft of at least 2.5 × 10 7 TNCs per kg (on the basis of pre-cryopreservation numbers), independent of the match grade (HLA) of the unit to the recipient. All patients received prophylaxis for graft-versus-host disease (GVHD) consisting of cyclosporine and mycophenolate mofetil beginning three days before infusion of the cord blood cells.
Sixteen days before the stem cell infusion date, we thawed the unit chosen for ex vivo expansion, enriched the unit for CD34 + (Fig. 2a) . Additional details of the final collected product can be found in the supplemental data (Supplementary Tables 2 and 3) . Of note, there were no mature T cells infused with the expanded graft. Despite the cell losses that occur with CD34 + cell selection, in all cases, the absolute number of CD34 + cells at the end of culture greatly exceeded the precryopreservation CD34 + cell number. The infused CD34 + cell dose derived from the expanded cord blood graft averaged 6 × 10 6 CD34 + cells per kg (range 0.93 × 10 6 to 13 × 10 6 ) versus 0.24 × 10 6 CD34 + cells per kg (range 0.06 × 10 6 to 0.54 × 10 6 ) (P = 0.0004) from the unmanipulated cord blood graft. There was no significant difference, however, in the average number of TNCs per kilogram dose infused between the unmanipulated and expanded cell grafts. We determined the kinetics of hematopoietic recovery and the relative contribution of the expanded and unmanipulated cord blood grafts to engraftment beginning 7 d after transplant. The time to an absolute neutrophil count (ANC) of ≥ 500 cells per µl was evaluable in nine out of ten patients in whom time to achieve an ANC of ≥ 500 cells per µl was shortened significantly (P = 0.002), with a median time of 16 d (range 7 -34 d). This compares quite favorably with a median time of 26 d (range 16-48 d; P = 0.002) in a concurrent cohort of 20 patients undergoing double cord blood transplantation at our institution with identical conditioning and post-transplant immunosuppressive regimen (Fig. 2b) . This cohort also did not differ significantly in age, weight, diagnosis or infused cell doses provided by the unmanipulated units (Supplementary Table 1) . Furthermore, previous publications have suggested that an ANC threshold of >100 cells per µl is strongly associated with a survival benefit after allogeneic stem cell transplant 12 . Among enrolled patients, the median time to achieve an ANC of >100 cells per µl was 9 d, versus 19 d in patients undergoing a double unmanipulated cord blood transplant (P = 0.006, data not shown). One patient experienced primary graft rejection. Of note, we did not observe any infusional toxicities or other safety concerns. The average follow-up time for this set of ten patients at the time of analysis was 354 d (range 77-806 d), and seven out of ten patients remain alive with no evidence of disease and with sustained complete donor engraftment. We observed acute grade 2 GVHD in all evaluable patients, except for one who had overall acute grade 3 GVHD. All patients responded to therapy. We have not observed chronic extensive GVHD, and three patients have been diagnosed with chronic limited GVHD.
We determined the contribution by the expanded or unmanipulated grafts to donor engraftment weekly in the first month after transplant beginning at day 7 on peripheral blood sorted cell fractions. In eight of the nine engrafted patients, there were sufficient numbers of sorted myeloid cells in the peripheral blood for evaluation, and, in each of these patients, there was a predominance of donor cell engraftment derived from the expanded cell graft in both the CD33 + and CD14 + cell fractions (Fig. 2c) . The one subject who was not evaluable at day 7 due to an insufficient quantity of cells had concurrent reactivation of human herpesvirus-6, a virus that has been shown to inhibit progenitor cell proliferation 13 . This patient was also the only one with neutrophil engraftment occurring beyond day 21 after transplant and the only engrafted patient with no contribution to engraftment observed from the expanded graft.
In four patients, an ANC of ≥ 500 cells per µl was attained at a time when the predominant contribution to myeloid engraftment was from the expanded cell graft (81%, 96%, 100% and 100% contribution to sorted CD33 + and CD14 + cell fractions (Fig. 2c)) . Three of these four subjects reached an ANC of ≥ 500 cells per µl exceptionally early (at 7, 7 and 9 d), with the fourth at day 16. However, in the remaining four patients who all engrafted early (≤ 21 d), ANC of ≥ 500 cells per µl occurred at a time when contribution to myeloid engraftment was derived from the unmanipulated graft. This may suggest a potential facilitating effect exerted by the ex vivo-expanded cells on the unmanipulated cord blood graft (Fig. 2c) .
We observed longer-term in vivo persistence of the expanded cell graft in two subjects. In one subject, analysis at day 240 after transplant revealed that a portion (10-15%) of the donor CD14 + , CD56 + and CD19 + cells were derived from the expanded graft but were no longer present by 1 year, at which point the donor engraftment was 100% from the unmanipulated cord blood graft ( Table 3 ). In the second subject at day 180 after transplant, the contribution to engraftment from the expanded cell population in CD33 + , CD14 + , CD56 + and CD19 + cells ranged from 25% to 66% of total donor engraftment ( Table 3) . However, the expanded graft did not contribute to CD3 + cell engraftment.
DISCUSSION
Our previous reports showed that expansion of mouse HSPCs can result from constitutive activation of Notch signaling 5 , and subsequent studies with mouse and human HSPCs have used recombinant ligands to activate endogenous Notch receptors with the goal of enhancing ex vivo generation of nongenetically altered hematopoietic repopulating cells for therapeutic intent [6] [7] [8] . Here we have shown that Notch-mediated expansion of cord blood stem/progenitor cells results in a marked expansion of hematopoietic precursors capable of rapid multilineage in vivo NOD-SCID reconstitution, while possibly retaining longerterm repopulating ability. Moreover, preliminary results from our phase 1 trial provide the first evidence that a key regulator of cell fate, the Notch pathway, can be used in a clinically compliant manner to generate a safe and potentially efficacious cell therapy product.
We observed substantially enhanced rates of myeloid engraftment, with a decrease in the median time to neutrophil recovery by more than 1 week, as compared to published times to neutrophil recovery after infusion of two unmanipulated units 14, 15 . Of note, the expanded cells contributed almost exclusively to initial myeloid engraftment observed at 1 week, demonstrating an enhanced capacity of the expanded cell graft to provide rapid myeloid recovery. Furthermore, all but one evaluable subject engrafted before day 21, independent of whether the expanded cell graft persisted in vivo. This is highly unusual in a double unmanipulated cord blood transplant, where 
, and is highly suggestive of a facilitating effect of the cultured cells in promoting engraftment from the unmanipulated cord blood unit, a hypothesis currently being explored.
The expanded cell population may also have retained a portion of longer-term repopulating stem/progenitor cells, as suggested by data from the two patients with in vivo persistence of cultured donor cells. The lack of in vivo persistence in the remaining patients could either be due to loss of stem cell self-renewal capacity during culture or to immune-mediated rejection. It has been well documented that in most patients who receive two unmanipulated units for CBT, only one unit contributes to persistent long-term engraftment 14, 16, 17 . The mechanisms responsible for this single-donor dominance remain ill defined; however, one possibility is immune-mediated rejection of the losing unit by the 'winning' graft. If this is correct, even if longer-term repopulating cells were present after culture of cord blood progenitor cells in the presence of Notch ligand, immune cells present in the unmanipulated unit would be expected to reject the expanded cell graft, which does not contain either mature or newly generated T cells. This hypothesis is further supported by recent studies showing an interferon-γ (IFN-γ) response by CD8 + CD45RO +/− CCR7 − effector memory T cells in the winning unit against the rejected one in patients undergoing double cord blood unit transplantation 18 . We included four patients from this phase 1 trial in these studies. Three of the four patients showed an IFN-γ response by cells derived from the unmanipulated cord blood unit in response to cells derived from the cultured unit, and in these patients only cells from the unmanipulated unit survived long term. In the fourth patient, failure to detect an IFN-γ response was associated with persistence of the cultured as well as the unmanipulated unit. Consequently, the persistence of long-term engrafting potential retained within the expanded progenitor cell population was not expected, and the >180-d in vivo persistence of progeny derived from the cultured cells in the two patients treated by CBT despite these barriers was surprising but consistent with our preclinical data in immunodeficient mice, in which ex vivo-expanded cord blood progenitors proved capable of secondary transplantation.
To our knowledge, this is the first demonstration of rapid hematopoietic engraftment derived from ex vivo-expanded hematopoietic progenitors. However, although rapid neutrophil engraftment has been shown in the patients treated to date, larger phase 2-3 studies will be required to test the hypothesis that the observed enhanced kinetics of engraftment will improve patient outcomes, including effects on overall survival, incidence of clinically important infections and time spent in the hospital.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/. 
ONLINE METHODS
Cell processing. We obtained human cord blood samples for research from normal deliveries under Swedish Medical Center Institutional Review Board (Seattle) approval and after consent was obtained. We incubated the units in ammonium chloride red blood cell lysis buffer (consisting of 16.6 g NH 4 Cl, 2 g NaHCO 3 and 74.4 mg EDTA per 2 l of water), washed them and suspended them in PBS with 2% human type AB serum (Gemeni Bio-Products). We incubated cells with CD34-specific antibody 12.8 (generated in our laboratory), followed by immunomagnetic bead-conjugated rat antibody to mouse IgM (Miltenyi Biotec), and we purified them with an Automacs (Miltenyi Biotec). We then froze the cells. In some cases, we enriched thawed cells for CD34 + or CD34 + CD38 − cells by flow cytometry.
For preclinical validation studies, frozen cord blood units obtained from the NHLBI or units obtained fresh, processed and cryopreserved were thawed with Dextran-human serum albumin 19 , and we selected for CD34 + cells with the Isolex 300i Magnetic Cell Selector (Baxter).
In vitro culture. We cultured cells for 17-21 d for preclinical studies and for 16 d for clinical grade cultures in non-tissue-culture-treated plates or 75-cm 2 tissue culture flasks (Falcon, Becton-Dickinson, or Nunc, Thermo Fisher Scientific) or Lifecell X-Fold cell culture bags (Baxter). We precoated culture vessels with Delta1 ext-IgG or human control IgG at 2.5 µg ml −1 (a density previously shown to be optimal for generation of NOD-SCID-repopulating cells 7 ), together with 5 µg ml −1 of fibronectin fragment CH-296 (Takara Shuzo Co) overnight at 4 °C, washed them with PBS and then blocked the vessels with PBS-2% BSA or human serum albumin at 37 °C.
We cultured cells in serum-free medium (StemSpan serum-free expansion medium, Stemcell Technologies) with recombinant human IL-3 (10 ng ml −1 ) IL-6 (100 ng ml −1 ), thrombopoietin (100 ng ml −1 ), Flt-3 ligand (300 ng ml −1 ) and stem cell factor (300 ng ml −1 ) (Invitrogen). Other media tested were QBSF-60 (Quality Biological Inc.), Stemspan H3000 (Stemcell Technologies), Stemline (Sigma-Aldrich), X-Vivo 10 and X-Vivo 20 (Cambrex) and Stempro 34 (Invitrogen). We obtained clinical-grade cytokines from CellGenix, and clinical grade ligand was prepared in the Fred Hutchinson Cancer Research Center Biologics Production Facility.
We initiated cultures with 6,000 CD34 + cells per well in 24-well plates, or 2.0 to 3.5 × 10 5 CD34 + cells per 75-cm 2 flask or 85-cm 2 bag and expanded them after 7-10 d into one 390-cm 2 tissue-culture bag or four to six 75-cm 2 tissue culture flasks. In some experiments, we further expanded cultures between days 10 and 14 into one or two additional 390-cm 2 bags or up to six additional flasks. We added fresh medium with cytokines every 3-4 d.
Flow cytometric analysis.
We performed immunofluorescence analysis as described previously 8 with FITC-labeled antibodies against CD34 and mouse CD45.1 (Becton Dickinson Pharmingen) or phycoerythrin-labeled antibodies against CD14, CD19, CD33, CD34, CD38 (Becton Dickinson Pharmingen), CD7 (8H8.1) and CD56 (Beckman Coulter) and PerCP-conjugated antibody against CD45 (Becton Dickinson Pharmingen) 7 . FITC-, phycoerythrin-or PerCP-conjugated, isotype-matched antibodies served as controls.
In vivo repopulation studies. We infused sublethally irradiated (325 cGy) NOD-SCID or NOD-SCID IL-2Rγ-null mice (obtained from an established breeding colony at the Fred Hutchinson Cancer Research Center and approved for use by the Fred Hutchinson Cancer Research Center Institutional Animal Care and Use Committee) with the progeny of 30,000 starting CD34 + cells per mouse via tail vein. In some cases, we depleted the total derived progeny of CD14 + cells with immunomagnetic beads. The number of cultured cells infused per mouse, on average, was 2.2 × 10 7 cells after culture with Notch ligand and 1.8 × 10 7 cells after culture with control human IgG. We combined CD34 + noncultured cells (30,000) with 2 × 10 5 irradiated (15 Gy) CD34 − cord blood cells as carrier cells. We assessed their repopulating ability at 10 d to 3 weeks after transplant with marrow removed from the knee joint of anesthetized mice. At 9 weeks after transplant, we killed the mice and assessed both femurs and tibias for the number and types of human cells. We determined the frequency of SRCs in limitingdilution assays by the method of maximum likelihood with L-CALC software (StemCell Technologies) from the proportions of engrafted recipients (≥0.5% human CD45 + cell engraftment) measured in groups of mice transplanted with the progeny of various numbers of starting cells.
We performed secondary transplants following a previously described method 20 . We resuspended marrow cells collected from bilateral femurs and tibias in Stemspan with IL-6 and stem cell factor at 50 ng ml −1 , incubated them for 48 h at 37 °C and then infused them into secondary NOD-SCID IL-2Rγ-null recipients at a ratio of one donor to one recipient.
Chimerism analysis. We performed chimerism testing on peripheral blood samples that were sorted by FACS into CD3 + , CD33 + , CD14 + , CD56 + and CD19 + cell fractions beginning on day 7 after transplant by a DNA-based assay for short tandem repeat loci. Statistical analyses. Data are presented as the means ± s.e.m. We determined the significance of the differences between groups by paired or unpaired twotailed t tests, (GraphPad software). 
